Genentech, Inc.

Corcept Therapeutics Incorporated

F. Hoffmann-la Roche Ag

Ge Healthcare UK Limited

Argenta Discovery Limited

Karen Williams

Simon Charles Goodacre

Robin D Clark

Hazel Joan Dyke

Nicholas Charles Ray

Christopher Hurley

David Edward Clark

Charles Ellwood

Paul M Blaney

Joseph P Lyssikatos

Stephen Colin Price

Huifen Chen

Jun Liang

Steven R Magnuson

Lewis J Gazzard

Birong Zhang

Mark S Stanley

Samuel S Kintz

John Gary Montana

Hazel Joan Hunt

George Hynd

Calum MacLeod

Yingjie Lai

Emanuela Gancia

Vickie H Tsui

Calum Macleod

Toby Jonathan Blench

Liang Bao

Peter H Crackett

Gwen Hickin

Nicolas C Ray

Wendy Lee

Vickie Hsiao-Wei Tsui

Kirk D Robarge

Aihe Zhou

Joy Drobnick

Adrian Christopher Simmonds

Pascal Savy

Susan Janet Fowler

Alison Claire Sweet

Timothy Stone

Christopher A Hurley

Samuel Kibtz

Pascal Pierre Savy

Pierre Pascal Savy

David A Clark

Michael Colin Cramp

Paul Matthew Blaney

David Middlemiss

Yan A Griffon

The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

1,7-diazacarbazoles and methods of use

The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy. 

Pyrazolopyridine compounds, compositions and methods of use

Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R, Rand Rare as defined herein.

Methods of use of diazacarbazoles for treating cancer

Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I. 

Azabenzothiazole compounds, compositions and methods of use

The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.

Fused ring azadecalin glucocorticoid receptor modulators

The invention relates to 1,7-diazacarbazole compounds of Formula (I), which are useful as kinase inhibitors, more specifically useful as checkpoint kinase I (chk1) inhibitors, thus useful as cancer therapeutics. 

Diazacarbazoles and methods of use

The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof. 

Janus kinase inhibitor compounds and methods

The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.

Azadecalin glucocorticoid receptor modulators

The invention relates to N-substituted azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to N-substituted azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

N-substituted azaindoles and methods of use

The present invention provides a class of modified pyrimidine compounds, compositions and methods of using the compounds as glucocorticoid receptor modulators.

Modified pyrimidine glucocorticoid receptor modulators

The invention relates to azabenzothiophenyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzothiophenyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. 

Aza-benzothiophenyl compounds and methods of use

The invention relates to azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Aza-indolyl compounds and methods of use

Azadecalin Glucocorticoid receptor modulators

The present invention provides a compound having the formula: wherein, n and m are; Xand Xare O; Ris a member selected from unsubstituted phenyl and substituted phenyl; Ris a member selected from hydrogen, &#x2014;CN, &#x2014;OR, -L&#x2014;C(O)R, -L&#x2014;S(O)R; Ris a member selected from unsubstituted benzyl and substituted benzyl; Ris a member selected from hydrogen and substituted or unsubstituted alkyl, wherein if Ris methyl, then -L-Ris not benzyl or &#x2014;C(O)&#x2014;O&#x2014;CH&#x2014;CH; and Lis a bond; and compositions and methods of using the compounds as glucocorticoid receptor modulators.

Growing community of inventors

Harlow, United Kingdom

Karen Williams